Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

H Lundbeck B (HLUNb)

Copenhagen
Currency in DKK
43.92
-0.42(-0.95%)
Closed
HLUNb Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
43.4444.16
52 wk Range
31.6249.38
Key Statistics
Edit
Prev. Close
44.34
Open
44.04
Day's Range
43.44-44.16
52 wk Range
31.62-49.38
Volume
319.56K
Average Volume (3m)
642.21K
1-Year Change
34.56%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HLUNb Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
50.50
Upside
+14.98%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

H Lundbeck B Company Profile

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Employees
5800
Market
Denmark

Compare HLUNb to Peers and Sector

Metrics to compare
HLUNb
Peers
Sector
Relationship
P/E Ratio
15.6x19.0x−0.7x
PEG Ratio
1.690.100.00
Price/Book
1.8x4.3x2.6x
Price / LTM Sales
2.0x3.8x3.2x
Upside (Analyst Target)
13.8%13.2%46.6%
Fair Value Upside
Unlock9.5%7.4%Unlock

Analysts' Recommendations

3 Buy
7 Hold
1 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 50.50

(+14.98% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.71
Dividend Yield
1.59%
Industry Median 1.03%
Annualised payout
0.7000
Paid annually
5-Years Growth
-21.84%
Growth Streak

People Also Watch

161.60
ALKb
-0.92%
122.70
TRIA
+1.07%
17.210
IDR
+0.12%
370.00
NETCG
+0.33%
529.0
NKT
-0.94%

FAQ

What Is the H Lundbeck B (HLUNb) Stock Price Today?

The H Lundbeck B stock price today is 43.92

What Stock Exchange Does H Lundbeck B Trade On?

H Lundbeck B is listed and trades on the Copenhagen stock exchange.

What Is the Stock Symbol for H Lundbeck B?

The stock symbol for H Lundbeck B is "HLUNb."

Does H Lundbeck B Pay Dividends? What’s The Current Dividend Yield?

The H Lundbeck B dividend yield is 1.59%.

What Is the H Lundbeck B Market Cap?

As of today, H Lundbeck B market cap is 41.99B.

What is H Lundbeck B Earnings Per Share?

The H Lundbeck B EPS is 2.71.

What Is the Next H Lundbeck B Earnings Date?

H Lundbeck B will release its next earnings report on 04 Feb 2025.

From a Technical Analysis Perspective, Is HLUNb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.